These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 19799084)
1. [Expressions of RASSF1A, Galectin-3 and TPO mRNA in papillary thyroid carcinoma and their clinical significance]. Xu MR; Chen Y; Zhou SR; Chi MM; Chen SL; Liu LY Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):356-60. PubMed ID: 19799084 [TBL] [Abstract][Full Text] [Related]
2. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003 [TBL] [Abstract][Full Text] [Related]
3. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294 [TBL] [Abstract][Full Text] [Related]
4. [Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases]. Yang QX; Shao CK; Feng ZY; Huang BQ; Han AJ; Xiong M; Zhao WL; Wu TT Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):678-81. PubMed ID: 15958307 [TBL] [Abstract][Full Text] [Related]
5. Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency. Espadinha C; Santos JR; Sobrinho LG; Bugalho MJ Clin Endocrinol (Oxf); 2009 Apr; 70(4):629-35. PubMed ID: 18710471 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217 [TBL] [Abstract][Full Text] [Related]
7. [Expression and clinical significance of galectin-3 in well-differentiated thyroid carcinoma]. Ouyang D; Chen FJ; Wei MW; Yang AK; Chen ZQ; Li QL; Chen YF Ai Zheng; 2005 Nov; 24(11):1367-71. PubMed ID: 16552965 [TBL] [Abstract][Full Text] [Related]
8. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis. Ma H; Yan J; Zhang C; Qin S; Qin L; Liu L; Wang X; Li N Int J Clin Exp Pathol; 2014; 7(11):7999-8007. PubMed ID: 25550843 [TBL] [Abstract][Full Text] [Related]
9. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions]. Tong J; Wang Y; Da JP Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical loss of thyroid peroxidase in papillary thyroid carcinoma: strong suppression of peroxidase gene expression. Tanaka T; Umeki K; Yamamoto I; Sugiyama S; Noguchi S; Ohtaki S J Pathol; 1996 May; 179(1):89-94. PubMed ID: 8691351 [TBL] [Abstract][Full Text] [Related]
11. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Weber KB; Shroyer KR; Heinz DE; Nawaz S; Said MS; Haugen BR Am J Clin Pathol; 2004 Oct; 122(4):524-31. PubMed ID: 15487449 [TBL] [Abstract][Full Text] [Related]
12. Galectin-3 and CD44v6 positivity by RT-PCR method in fine needle aspirates of benign thyroid lesions. Matesa N; Samija I; Kusić Z Cytopathology; 2007 Apr; 18(2):112-6. PubMed ID: 17397496 [TBL] [Abstract][Full Text] [Related]
14. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators. Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527 [TBL] [Abstract][Full Text] [Related]
15. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. Aron M; Kapila K; Verma K Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889 [TBL] [Abstract][Full Text] [Related]
17. Differential expression of thyroperoxidase mRNA splice variants in human thyroid tumors. Le Fourn V; Ferrand M; Franc JL Biochim Biophys Acta; 2004 Jun; 1689(2):134-41. PubMed ID: 15196594 [TBL] [Abstract][Full Text] [Related]
18. TPO gene mutations associated with thyroid carcinoma: Case report and literature review. Zhu H; Peng YG; Ma SG; Liu H Cancer Biomark; 2015; 15(6):909-13. PubMed ID: 26406404 [TBL] [Abstract][Full Text] [Related]
19. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma. Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma. Baek SK; Woo JS; Kwon SY; Lee SH; Chae YS; Jung KY Laryngoscope; 2007 May; 117(5):911-6. PubMed ID: 17473695 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]